Vigilance

Blood and tissue establishments must record any deviations observed in their activities. If the deviation is classified as a serious adverse event or a serious adverse reaction, Fimea must be notified of it. In addition, blood and tissue establishments report annually to Fimea a summary of any serious adverse reactions or adverse events linked to blood products and tissue and cell grafts they have observed. These vigilance reports delivered to Fimea that meet the criteria laid down in the Directives will be further reported to the European Commission. The Commission monitors vigilance reports from EU Member States and summarises them annually. 

Serious adverse events and serious adverse reactions are reported using appropriate forms. The forms are sent either by email or by post to the registrar’s office at Fimea.

EN Turvatoiminta / UKK